We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+11.94%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.73B
AUM Growth
+$6.46M
Cap. Flow
-$42.8M
Cap. Flow %
-2.48%
Top 10 Hldgs %
30.81%
Holding
279
New
77
Increased
40
Reduced
47
Closed
83

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$14.4M
2
ILMN icon
Illumina
ILMN
+$11.2M
3
ICUI icon
ICU Medical
ICUI
+$10.4M
4
OLK
Olink Holding AB (publ) American Depositary Shares
OLK
+$9.5M
5
OM icon
Outset Medical
OM
+$8.23M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.5M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.9M
3
LUNG icon
Pulmonx
LUNG
+$10.1M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$9.8M
5
EVH icon
Evolent Health
EVH
+$7.06M

Sector Composition

Rank Sector Weight
1 Healthcare 34.81%
2 Industrials 0.32%
3 Materials 0.15%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNX icon
126
Annexon
ANNX
$873M
$2.31M 0.13%
+374,630
New +$2.03M
VERU icon
127
CALL
Veru
VERU
$46.7M
$2.3M 0.13%
20,000
– –
ESPR
128
DELISTED
Esperion Therapeutics
ESPR
$2.23M 0.13%
332,123
+120,000
+57% +$824K
PFE icon
129
Pfizer
PFE
$150B
$2.19M 0.13%
+50,000
New +$2.43M
AVXL icon
130
CALL
Anavex Life Sciences
AVXL
$316M
$2.06M 0.12%
200,000
– –
AMRS
131
PUT
DELISTED
Amyris Inc.
AMRS
$2.04M 0.12%
+700,000
New +$1.91M
GOSS icon
132
PUT
Gossamer Bio
GOSS
$86.8M
$2.04M 0.12%
169,900
+69,900
+70% +$868K
AMLX icon
133
Amylyx Pharmaceuticals
AMLX
$2.6B
$1.93M 0.11%
68,652
+58,102
+551% +$1.45M
BSX icon
134
Boston Scientific
BSX
$74.5B
$1.88M 0.11%
+48,635
New +$1.95M
RVMD icon
135
Revolution Medicines
RVMD
$44B
$1.87M 0.11%
+95,000
New +$2.09M
DNA icon
136
PUT
Ginkgo Bioworks
DNA
$486M
$1.87M 0.11%
15,000
-28,750
-66% -$3.43M
ICAD
137
DELISTED
iCAD Inc
ICAD
$1.85M 0.11%
880,558
+207,569
+31% +$680K
GHRS icon
138
GH Research
GHRS
$2.08B
$1.84M 0.11%
158,327
-50,200
-24% -$633K
SNCE
139
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.78M 0.1%
55,320
– –
NGM
140
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.77M 0.1%
+135,696
New +$2.06M
AKYA
141
DELISTED
Akoya BioSciences
AKYA
$1.73M 0.1%
+147,500
New +$1.94M
RXDX
142
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$1.72M 0.1%
+29,188
New +$1.34M
KOD icon
143
CALL
Kodiak Sciences
KOD
$2.72B
$1.55M 0.09%
+200,000
New +$1.94M
VRDN icon
144
Viridian Therapeutics
VRDN
$2.59B
$1.54M 0.09%
75,003
-30,457
-29% -$548K
GERN icon
145
PUT
Geron
GERN
$1.01B
$1.46M 0.08%
+623,300
New +$1.4M
NYXH
146
Nyxoah
NYXH
$158M
$1.42M 0.08%
221,949
– –
MRTX
147
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.4M 0.08%
+20,000
New +$1.48M
RETA
148
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$1.4M 0.08%
+55,596
New +$1.54M
IOVA icon
149
Iovance Biotherapeutics
IOVA
$3.05B
$1.39M 0.08%
+144,528
New +$1.67M
BIIB icon
150
Biogen
BIIB
$30.9B
$1.33M 0.08%
5,000
-96,711
-95% -$20.5M
4 5
6
7 8

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2022 Portfolio in Review

As of Q3 2022, Pura Vida Investments held 279 positions worth $1.73B, up 0.38% from $1.72B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Pura Vida Investments's Q3 2022 filing shows 77 new, 40 increased, 47 reduced and 83 closed positions. Its largest new stake was Illumina: 56,540 shares worth $10.5M. The largest sale was Biogen, an estimated $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Industrials and Materials.

  • Pura Vida Investments's largest Q3 2022 buy was Illumina: 56,540 shares worth $10.5M.
  • Pura Vida Investments added most to United Therapeutics in Q3 2022, an estimated $14.4M increase.
  • Pura Vida Investments's biggest Q3 2022 reduction was Biogen, cutting an estimated $20.5M.
  • Pura Vida Investments fully exited Alnylam Pharmaceuticals in Q3 2022, selling an estimated $13.9M.
  • Pura Vida Investments's ten largest holdings make up 31% of its $1.73B portfolio in Q3 2022.
  • Pura Vida Investments opened 77 new positions and closed 83 in Q3 2022.
  • Pura Vida Investments's portfolio value rose 0.38% quarter-over-quarter to $1.73B.

Based on Pura Vida Investments's 13F filing for Q3 2022, filed 14 Nov 2022.